State of the Scan — November 2026
A monthly synthesis across the whole corpus · updated 15 Nov 2026
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.
State of the Scan — November 2026
The scan this month tells a story of consolidation: oncology and diagnostics are trading early-detection hype for hard biomarker discipline, while frailty, aging-adjacent metabolism, and generalist AI models quietly move from the margins to the center.
The big picture
For much of this year, the loudest signals in biomedical literature came from early cancer detection, precision oncology genomics, and splashy aging/longevity claims. This month, all three cooled significantly — early cancer detection down 40%, precision oncology and genomics down 39%, aging and longevity down 36%. That's not a sign these fields are dying; it's a sign the easy headlines have been written. What's left is denser, more technical work: validating liquid biopsy panels against real clinical endpoints, refining which biomarkers actually predict response rather than just correlate with it, and replacing "one-size-fits-all" cancer treatment sequencing with individualized, biomarker-guided trajectories.
At the same time, a cluster of topics that sound almost unrelated — frailty, sarcopenia, cardiometabolic risk, large language models — are surging by 400-900%. These aren't random spikes. They reflect a convergence: AI tools and composite risk indices are increasingly being pointed at the same population — older, multimorbid, community-dwelling adults — to try to predict decline before it happens. The center of gravity is shifting from "find the cancer early" to "quantify the whole-person risk picture early."
What's heating up
- Frailty and sarcopenia (+900% / +500%) — Geriatric constructs like the Clinical Frailty Scale are being formalized into quantitative research endpoints, often paired with metabolic markers, signaling a push to treat frailty as a measurable, modifiable risk factor rather than a vague clinical impression.
- Large Language Models (+500%) — LLMs are being validated alongside blood-based inflammatory indices as scalable tools for risk stratification and diagnostic interpretation — part of a broader move to test whether frontier AI can generalize across clinical domains, not just narrow tasks.
- Targeted Therapy and Antibody-Drug Conjugates (+500% / +400%) — Biomarker-guided treatment selection continues to deepen, with ADCs maturing as a delivery mechanism that pairs targeting precision with cytotoxic payloads — notably visible in esophageal cancer (+400%), a tumor type gaining fresh attention.
- Allogeneic Hematopoietic Stem Cell Transplantation and Multiple Myeloma (+400% / +350%) — Myeloid and plasma-cell malignancies are seeing renewed momentum, consistent with the broader bispecific-engager and CAR-T convergence (e.g., BCMA-targeted ciltacabtagene autoleucel) reshaping treatment sequencing in blood cancers.
- Cardiometabolic Risk and Community-Dwelling Older Adults (+400% each) — Composite indices like the Triglyceride-Glucose Index and its derivatives (TyG-ABSI) are being tested as predictors that bridge metabolic and frailty risk in aging populations studied outside hospital settings.
Cooling / quieter
- Rare diseases, aging/longevity, and AI diagnostics broadly (-44%, -36%, -33%) — These remain active but are past their hype peak; expect fewer splashy claims and more incremental, validation-stage work.
- Early cancer detection and precision oncology genomics (-40%, -39%) — The foundational biomarker science hasn't disappeared — it's being absorbed into more specific clusters like ctDNA kinetics and liquid biopsy convergence.
- Single-variable disease topics (-100%) — Endometrial cancer, liver metastasis, epigenetic regulation, and diagnostic precision as standalone topics have essentially vanished this month, likely folded into the larger composite and multi-omic frameworks now dominating the field.
Themes to watch
Incretins go beyond the needle. The cardiometabolic drug story is diversifying past injectable GLP-1 agonists. Oral small-molecule entrants like Aleniglipron (a non-peptide GLP-1 receptor agonist) and multi-receptor formats are emerging alongside liver-directed metabolic therapies — suggesting the next phase of this category will be as much about route of administration and receptor combinations as raw efficacy.
Liquid biopsy and ctDNA mature into kinetics, not snapshots. Rather than one-off blood tests for early detection, the field is shifting toward serial, kinetic monitoring of circulating tumor DNA across colon, pancreatic, breast, ovarian, and colorectal cancers. Trials like CIRCULATE exemplify this: tracking molecular residual disease over time, not just flagging it once. Methylation-based multi-gene panels (DCDC1, RARB, ZNF260) are part of the same push toward quantitative rigor.
Blood cancers are the proving ground for next-gen immune engineering. CAR-T therapy, bispecific T-cell engagers, and antigen-targeted antibodies are converging on multiple myeloma and myeloid malignancies, with BCMA as the dominant target. In parallel, mechanistic work on myelodysplastic syndrome and AML is zeroing in on aberrant RNA splicing (the MBD1-L isoform, linked to WTAP dysregulation) as a driver of epigenomic dysfunction — tying molecular biology directly to the therapies being designed to exploit it.
Foundation models and composite indices are replacing single-purpose tools. Just as SKELEX demonstrates a shift from narrow diagnostic algorithms to self-supervised vision models generalizing across imaging tasks, the frailty/cardiometabolic space is replacing single biomarkers with composite indices (TyG-ABSI, Remnant Cholesterol, Clinical Frailty Scale). The common logic: combine signals rather than rely on one number.
The through-line
If there's one throughline this month, it's a move away from singular, narrow signals — one biomarker, one scan, one algorithm — toward composite, longitudinal, and multi-modal approaches, whether that's serial ctDNA kinetics, frailty-metabolic indices, or foundation models trained across imaging tasks. The excitement hasn't faded; it's been redirected from detection toward integration.
Not medical advice.
Articles referenced 18 verified on PubMed
- Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
- Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype.
- Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
- Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study
- Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trial.
- Development and external validation of a machine learning prediction model for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children using routine blood parameters: a retrospective cohort study.
- Prognostic value of circulating tumor DNA in treated gastric cancer patients: A systematic review and meta-analysis.
- Spatially Fractionated Induction Radiotherapy to Widen the Therapeutic Window in Locally Advanced Non-Small-Cell Lung Cancer (SPARROW): Study Protocol of a Multicenter, Randomized, Open-Label Seamless Phase I/II Trial.
- Early-life sugar restriction causally reduces adult cancer incidence and slows biological aging.
- Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer.
- Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience.
- A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing.
- Data-driven prioritization of high-risk individuals for weight loss interventions
- Multi-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer
- Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
- Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
- Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
- Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.